Business Development Fp A

Hema Sampath

Cell: 224-***-**** E-mail: *************@*****.***

Dedicated Financial Controller and management consultant, well regarded by clients, business partners, and senior executives as a key advisor, creative problem solver, and results-driven finance professional. Demonstrated success in P&L management, with proven ability to deliver topline commitments, tightly manage operational budgets, wholesaler inventory, improve P&L scenario, and implement crucial change initiatives while simultaneously guiding teams through complex process and business changes. Backed by solid credentials – experience with Large Consumer Goods, Big Pharma, Master’s in International Business. Areas of Expertise

P&L Management, Forecast, Reporting Business Development

Strategic Financial Planning Valuation and Portfolio Fit Assessment

Leadership & Supervision Treasury: Cash Flow Mgmt.& Capital Infusions

Capital Budgets & Audit Management Financial Research & Analysis

Strategic Pricing Advanced Proficiency in Powerpoint, Excel Career Progression

Abbott Laboratories

Abbott Nutrition International (ANI) Division - Chicago, Illinois Divisional Vice President and Controller, ANI – 2020 -Present Lead FP&A activities for Nutrition International business of Abbott Nutrition Division with annual Sales

~$5Bn. Responsible for P&L of Worldwide Commercial Operations including Pacific Asia, Japan, Australia and New Zealand, Latin America, Middle East, Africa, Western and Eastern Europe. Scope of role has included delivering on financial commitment of the operations, driving portfolio investment prioritization and trade-offs, regional expansion plans, setting strategic direction for the business through business planning, prioritization of Innovation through appropriate valuations, Strategic Business Development and delivering on Margin and Profitability goals. Leadership responsibilities for > 400 Finance Professionals worldwide. On track to delivering above 2022 Plan Sales and Margin. Abbott Rapid Diagnostics Division - Chicago, Illinois Divisional Vice President and Controller, Infectious Disease Developed (IDD) Markets – 2017-2019 Lead FP&A activities for the IDD Business Unit of Abbott Rapid Dx Division with annual Sales >$3.0Bn. Responsible for a fully integrated P&L including Commercial Operations for North America, Western Europe, Japan, ANZ, worldwide Manufacturing Operations and R&D. Scope of role has included integration of the Alere acquisition into Abbott’s operations, driving site and facilities closures, restructuring Salesforce and Commercial operating entities, FP&A transformation, setting strategic direction for the business through business planning, prioritization of Investments and Innovation through appropriate valuations, driving synergies related to the acquisition and Strategic Business Development. Achieved and/or exceeded 2017, ’18 and ‘19 Plan Sales and Margin.

Abbott Nutrition - Columbus, Ohio

Senior Finance Director and Controller, US Pediatric Nutrition – 2014-2017 Head of Finance for US Pediatric Division with annual Sales >$1.5Bn. Responsible for P&L, setting strategic direction for the business through Long- and Short-term business planning, Innovation valuations, Margin and Productivity Initiatives, Resource prioritization, Strategic Business Development, Contracting Strategy on Infant formula tenders through rigorous Game Theory analytics and Investor Relations communications. Achieved and/or exceeded 2014-16 Plan Sales and Margin for US Pediatric Business Unit. Hema Sampath Résumé, Page Two

Abbott Nutrition – Columbus, Ohio

Finance Director and Controller, Global Research and Development – 2012-2014 Global Finance Head with oversight of diversified Staff across Asia (Singapore, India, China), Europe and US. Responsible for P&L, strategic portfolio investments, Capital investments in Product Development, identifying creative financing solutions for longer-term research initiatives, out-partnering activities in Asia, Long and Short-term Business Plans. Led strategic portfolio trade-offs and secured >$20MM capital investment for a Pilot Plant in Asia, in support of Emerging Market Growth. Eli Lilly and Company – Indianapolis, IN (www.lilly.com) Director, Corporate Business Development – 2007 to 2012 Responsible for development of deal valuation and commercial business case including deal NPV, asset profile, resourcing required to drive commercial/functional success across geographies, appropriate, objective representation of business case to Executive Leadership and commercial deal finalization. Led valuations on >100 assets over four years as well as responsible for closing 6 deals (in-licensing and acquisition).

Director / Asst. Financial Controller, US Operations, August 2002 to 2006 Direct all FP&A, accounting, wholesaler, and audit activities / processes of the US operations of Eli Lilly and Company. Review and recommend significant Forecast changes, consolidation and reporting of results, review and trade-off of Short-term and Strategic Plan issues, collaborate with senior management team on strategic initiatives. Responsible for US affiliate P&L, Inventory management with Pharmaceutical Wholesalers and Budget management for Sales and Marketing support functions with operating expenses > $ 400 mil. Provide overall management of Planning/Forecasting/Reporting staff of 12. Key Contributions:

Led successful business restructuring effort to drive operational efficiency in the US Operations.

Implemented comprehensive restructuring plan in 2004 with turnaround time of less than 2 months that resulted in significant operational efficiency in the following three years.

Leveraged relationships with senior and mid-level executives across the Sales and Marketing Support functions to develop a prioritization / trade-off plan.

Implemented Wholesaler Inventory Management program in the US marketplace:

Led successful efforts at implementing program and managing wholesaler inventory tightly through conversion of US distribution operations to SAP.

Resulted in no negative financial exposure to the Corporation from the conversion. Pre- shipments of $300MM + managed tightly resulting in low post-conversion inventory levels.

Monthly and Quarterly P&L Close:

Responsible for closing monthly and quarterly P&L including Sales ledger with annual revenue of $10BN+, Operating expense and Other Income/Deductions ledgers.

Primary accountability for Reporting and interpreting results to Corporate Accounting, Investor Relations and Communications group.

Lead certification of financial results process with senior executives for SEC disclosure purposes. Business Operations Manager, US Operations, August 2001 to August 2002 Served as critical member of launch management team that drove a very successful launch of a key Neuroscience product in the US marketplace.

Responsible for implementation of Brand strategy by the Salesforces at the time of Brand launch.

Led a highly motivated team through development of operational strategy and key metrics that drove desired performance by the Salesforces.

Forged linkages between Brand and the Field through periodic, frequent communications that resulted in a commonly understood set of metrics, and seamless implementation framework with Sales far exceeding expectations 12 months post-launch. Hema Sampath Résumé, Page Three

Financial Planning Analyst, July 1999 – July 2001

Primary responsibility of owning the Planning process including setting of Financial targets for various therapeutic areas and support functions, consolidation and review of financials with senior executives as well as driving the right trade-off decisions for both the short-term and Long-Range Plans.

Led critical Strategic Planning process within the US operations through expiry of the Prozac patent in 2001.

Resulted in a clearly outlined operational Plan with prioritized investment decisions that paved the way for Corporate transition from patent expiry to portfolio growth. Treasury Analyst, Latin America, April 1997- June 1999 Responsible for managing Balance Sheet exposure from currency devaluations in Latin American markets.

Developed and implemented a well thought out Balance Sheet management strategy especially focused on inventory management in Brazil that resulted in minimizing the exposure as a result of the devaluation of the Real by 47% in early 1999.

Successfully developed and presented capitalization business cases to senior executives that resulted in capital infusion of > $ 20 mil into three key Latin American markets. Pricing Analyst, Latin America and Asia-Pacific, November 1995 – March 1997 Responsible for developing Pricing strategies for products in the Infectious Diseases and Cardiovascular therapeutic areas as well as portfolio pricing tactics in the Asian and Latin American markets.

Numerous bids/tenders won in regional markets from successful development of pricing strategy.

Developed and rolled out a Pricing workshop designed to improve regional understanding of Pricing strategy, concepts and tactics and further enhance pricing knowledge. Trained pricing, sales and marketing professionals in >25 countries through the workshop. Resulted in stemming price erosion in major markets on key products in bids/tenders. The Hudson Institute - Indianapolis, IN One of the largest think tanks in the nation. Policy Analyst, June 1994 – October 1995

Consultant for Eli Lilly and Company on strategic manufacturing sourcing within the framework of Free Trade Pacts in Latin America and Asia Pacific.

Developed sourcing strategy in both regions that would enable Lilly manufacturing to source products within the region, thereby eliminating significant tariffs paid as a result of not leveraging intra-regional Free Trade pacts.

Education

University of Southern California – Los Angeles, CA

(Master’s in Policy / International Business), May 1993 Madras University – Chennai, India

Master’s Degree in Economics

Reply To

Cell: 224-***-**** E-mail: *************@*****.***

Contact this candidate